Raymond James Financial Services Advisors Inc. Sells 398 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Raymond James Financial Services Advisors Inc. trimmed its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 2.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 16,849 shares of the company’s stock after selling 398 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Invesco Biotechnology & Genome ETF were worth $1,109,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of PBE. JPMorgan Chase & Co. acquired a new position in shares of Invesco Biotechnology & Genome ETF during the fourth quarter valued at about $1,772,000. Morgan Stanley grew its position in Invesco Biotechnology & Genome ETF by 14.0% during the 4th quarter. Morgan Stanley now owns 209,952 shares of the company’s stock worth $13,331,000 after purchasing an additional 25,780 shares during the last quarter. Susquehanna International Group LLP acquired a new position in Invesco Biotechnology & Genome ETF during the 4th quarter valued at approximately $1,079,000. Gerber Kawasaki Wealth & Investment Management raised its holdings in shares of Invesco Biotechnology & Genome ETF by 6.8% in the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 201,088 shares of the company’s stock worth $12,622,000 after buying an additional 12,764 shares during the last quarter. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter worth $623,000.

Invesco Biotechnology & Genome ETF Price Performance

Shares of PBE opened at $61.33 on Monday. The company’s fifty day moving average price is $64.55 and its 200-day moving average price is $61.68. Invesco Biotechnology & Genome ETF has a 1-year low of $52.47 and a 1-year high of $67.76. The firm has a market capitalization of $233.05 million, a PE ratio of 16.61 and a beta of 0.92.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.